You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

marginal zone lymphomas

Showing 1 - 25 of 2,493
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Marginal Zone Lymphoma Trial ([68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose)

Not yet recruiting
  • Marginal Zone Lymphoma
  • (no location specified)
Nov 6, 2023

Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma Trial in Worldwide (Ibrutinib, Rituximab)

Recruiting
  • Marginal Zone Lymphoma
  • +2 more
  • Yvoir, Belgium
  • +36 more
Nov 4, 2022

Marginal Zone Lymphoma Trial in Austria, Italy, Switzerland (Tafasitamab, Acalabrutinib)

Recruiting
  • Marginal Zone Lymphoma
  • Wien, Austria
  • +9 more
Jul 13, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma Trial in France (Atezolizumab, Obinutuzumab,

Completed
  • Follicular Lymphoma
  • +3 more
  • Angers, France
  • +24 more
Jan 9, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Trial in Milano (intralesional rituximab, supplemental autologous

Completed
  • Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
  • intralesional rituximab
  • supplemental autologous serum
  • Milano, Italy
    Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte T
Aug 2, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • Scottsdale, Arizona
  • +1 more
Aug 10, 2021

Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)

Recruiting
  • Marginal Zone Lymphoma
  • Obinutuzumab, lenalidomide
  • Tianjin, Tian, China
    Institute of Hematology & Blood Diseases Hospital
Apr 27, 2023

B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

Active, not recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-OX40 Antibody BMS 986178
  • +3 more
  • Palo Alto, California
    Stanford University, School of Medicine
May 3, 2022

Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,

Terminated
  • Non-Hodgkins Lymphoma
  • +6 more
  • Huntsville, Alabama
  • +1 more
May 5, 2022

Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor

Recruiting
  • Non-Hodgkin's Lymphoma
  • +18 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Mar 11, 2021

OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

Not yet recruiting
  • OR Regimen Refractory Marginal Zone Lymphoma
  • obrutinib, rituximab
  • (no location specified)
Nov 12, 2023

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +23 more
Dec 28, 2022

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +71 more
  • Chicago, Illinois
  • +5 more
Oct 8, 2021

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,

Recruiting
  • Grade 1 Follicular Lymphoma
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Dec 7, 2021

Marginal Zone Lymphoma and Its Prognostic Role

Recruiting
  • Marginal Zone Lymphoma
    • Dijon, France
    • +22 more
    Jan 17, 2023

    Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

    Not yet recruiting
    • Marginal Zone Lymphoma
    • Mosunetuzumab + Lenalidomide
    • +3 more
    • (no location specified)
    Aug 16, 2023

    Molecular Taxonomy of Nodal Marginal Zone Lymphoma

    Not yet recruiting
    • Nodal Marginal Zone Lymphoma
      • Paris, France
      • +2 more
      Jan 17, 2023

      Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

      Not yet recruiting
      • Follicular Lymphoma
      • +2 more
      • Boston, Massachusetts
        Dana-Farber Cancer Institute
      Mar 13, 2023

      Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)

      Not yet recruiting
      • Relapsed/Refractory Marginal Zone Lymphoma
      • Guangzhou, Guangdong, China
      • +10 more
      Oct 8, 2023

      Lymphoma Trial (Ultra Low Dose 4 Gy Radiation)

      Not yet recruiting
      • Lymphoma
      • Ultra Low Dose 4 Gy Radiation
      • (no location specified)
      Jun 30, 2023

      Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)

      Active, not recruiting
      • Indolent Non-hodgkin Lymphoma
      • Shanghai, China
        Ruijin hospital, school of medicine, Shanghai jiao tong universi
      Oct 3, 2022

      Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

      Recruiting
      • Follicular Lymphoma
      • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 20, 2023